Let’s Get Started!
Fill out the form and we’ll contact you for an introductory call.
Discover, Develop and Deliver Real-World Evidence
For data that makes a difference, look no further than the authority in real-world evidence. STATinMED is a leading real-world evidence generator, helping HEOR, market access, and commercial teams discover improve decisions and drive innovation and value.
It's what we do best. Contact us!
Why STATinMED?
We’re the authority in real-world evidence.
Our approach and real-world data insights are foremost in the industry based on hundreds of combined experience years and >1000 peer-reviewed publications in dozens of therapeutic areas.
Real-World Evidence for HEOR Strategy
Our real-world evidence informs Health Economics and Outcomes Research strategy, with HEOR data insights from Phase II/III through post-launch to support product value.
Phase II/III
Discover Unmet Needs and Patient Centricity
Learn the needs and challenges of high burden segments to identify the most appropriate patient population for your drug, and support early-stage evidence and pre-launch commercialization planning.
Mapping the Disease Landscape and Patient Journey
Gain comprehensive insights about disease landscape, comorbidities, treatment utilization, and specialty providers to drive future study design and evidence planning.
Epidemiology Support Services
Ensure the benefits, risks, value, and potential of products from commercial, Medicaid, and Medicare claims to support forecasting and economic modeling.
Measuring the Burden of Illness
Measure the impact of a disease to inform healthcare interventions, treatments, policies, and priority settings, with publication opportunities to support communications with payers and policy makers.
Post-Launch
Determining Feasibility With Real World Evidence
Drive strategic decision-making, shape future study design, and support value communications with real-world evidence (RWE) focused on practical treatment utilization rates.
Comparative Effectiveness through HEOR
Generate evidence about adherence and impact on serious clinical outcomes for specific subsets of patients, including mortality for those with rare or chronic conditions.
Value, Communication, and Support
Prioritize patient access to therapy, negotiate contracts for improved formulary status, or realize cost savings with utilization of a particular therapy over standard of care.
“The amazing research collaboration between STATinMED and our team has already led to a comprehensive body of evidence to inform confident decision-making for many patients.”
Joint Partnership Alliance, Real-World Evidence Executive
Real-World Evidence for Market Access and Commercialization Success
Our real-world data services support strategy, product launch, and commercialization success for life sciences companies.
Clinical Eligibility through Real World Data
Clinical Eligibility through Real World Data
Allow data-driven decision-making and account prioritization based on the addressable market
Measuring Opportunity Loss
Measuring Opportunity Loss
Identify clinically appropriate providers with high opportunity to support field teams
Prioritize Payer-Provider Insights
Prioritize Payer-Provider Insights
Discover the impact of utilization management practices on patient access and adherence to therapy to support discussions on value-based care
Gain Competitive Indication Share
Gain Competitive Indication Share
Gain indication-specific market share within an account to support contract negotiations
Gain Real World HCO-HCP Insights
Gain Real World HCO-HCP Insights
Prioritize HCPs in a complex market based on share of patients with favorable access to newly launched therapy
Robust, Current & Relevant Real-World Data
Real-Time Data
Real-world data repository from 2014 to present (30-day lag)
Care Settings
Longitudinal tracking across pharmacy and sites of care
Nationwide Reach
Patients from all US geographic regions
Rapid Access
No delay to project kick-off
Patient Universe
Population = 300+ MM; de-identified, tokenized, HIPAA-compliant
Channel Capture
Commercial, Medicare FFS/Advantage, Medicaid (50 states)
Patient Tracking
Linked via direct matching algorithm
Payer Detail
Account details at transaction level
Providers & Rx
97% of HCP specialties; full life cycle of claims
Use Cases
Find out how leaders in life sciences use our real-world data and evidence solutions.
Discover Opportunity
Differentiated market share for multi-indication product
Geographic-specific variations and other categorical variables about the total addressable market
Influential and clinically appropriate providers and early adopters within a HCO
Payer access structures impact patient resource utilization and behaviors
Realize Maximum Value
Leverage insights for the indication-specific market share to support contract negotiations
Identify clinically-eligible lives to inform data-driven decision-making and account prioritization
Use IDN/HCO-HCP insights to identify high-opportunity providers to support field teams
Understand the impact of utilization management practices and adherence to support value-based care
Case Studies
See how our real-world evidence improved and accelerated
decisions for these life science companies.
CASE STUDY
Segmentation: Powerful Insights about Patients with Rare Disease
CASE STUDY
Clinical Burden of Illness: Co-infection vs Monoinfection
